Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma

Ruiqi Liu(Huazhong University of Science and Technology), Tongsen Zheng(Harbin Medical University), Meng Zhou(University of Science and Technology of China), Shuangjia Wang(First Affiliated Hospital of Xiamen University), Jiguang Han(Third Affiliated Hospital of Harbin Medical University), Yuejin Li(Shandong First Medical University), Yingjian Liang(Harbin Medical University), Jianhua Nie(Third Affiliated Hospital of Harbin Medical University), Benjie Xu(Harbin Medical University), Shuli Tang(Third Affiliated Hospital of Harbin Medical University), Li Wu(Zhejiang Chinese Medical University), Binlin Lin(Harbin Medical University), Yanqiao Zhang(Harbin Medical University), Huawen Shi(Harbin Medical University), Chunhui Zhang(Third Affiliated Hospital of Harbin Medical University), Guangyu Wang(Tongji University), Boshi Sun(Harbin Medical University), Kunmei Gong(First People's Hospital of Yunnan Province), Lantian Tian(Affiliated Hospital of Qingdao University), Lianxin Liu(Harbin Medical University), Jiabei Wang(University of Science and Technology of China)
Cancer Letters
November 29, 2018
Cited by 144


Related Papers